Optimal Dose of Surfactant for Preterm Infants With Respiratory Distress Syndrome
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
In preterm infants with neonatal respiratory distress syndrome (RDS), exogenous pulmonary
surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to
reduce neonatal incidences of bronchopulmonary dysplasia(BPD) and/or death. But not all
preterm infants with RDS can be beneficial. Otherwise, the international neonatal acute RDS
(NARDS) collaborative group provides the first consensus definition for NARDS in 2017. And
whether or not PS being beneficial in preterm infants with NARDS remains unknown.
Phase:
N/A
Details
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Collaborator:
Children's Hospital of Chongqing Medical University